Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

Inozyme Pharma, a US-based developer of mineralisation disorder treatments spun out of Yale University, received $67m in series A2 funding yesterday from investors including pharmaceutical firms Novo and Sanofi, the latter through its Sanofi Ventures unit.
The round was co-led by Pivotal BioVenture Partners, the healthcare investment firm formed by property developer Nan Fung, and venture capital firm Sofinnova Investments.
Investment managers RA Capital Management and Cowen Healthcare Investments, hedge fund manager Rock Springs Capital and VC firms…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in